Vitamin D and cancer: Clinical aspects

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 25, Issue 4, 2011, Pages 605-615

  Woloszynska Read, Anna ^a   Johnson, Candace S ^a   Trump, Donald L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

calcitriol; clinical trials; vitamin D

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; CARBOPLATIN; COLECALCIFEROL; CYTARABINE; DEXAMETHASONE; DOCETAXEL; ESTROGEN; GEFITINIB; PACLITAXEL; PARICALCITOL; PLACEBO; PLATINUM DERIVATIVE; SEOCALCITOL; TAXANE DERIVATIVE; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC KIDNEY DISEASE; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; ESTROGEN THERAPY; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOPARATHYROIDISM; INFECTION; KIDNEY CANCER; LIVER CANCER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEPHROLITHIASIS; NEUROMUSCULAR DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; STROKE; THROMBOEMBOLISM; TOXICITY; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 80052244023     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2011.06.006     Document Type: Review

References (94)

1. E. Giovannucci Epidemiology of vitamin D and colorectal cancer: casual or causal link? The Journal of steroid biochemistry and molecular biology 121 1-2 2010 Jul 349 354
2. E. Giovannucci The epidemiology of vitamin D and cancer incidence and mortality: a review (United States) Cancer Causes and Control 16 2 2005 Mar 83 95 (Pubitemid 40691207)
3. M.P. Purdue, D.M. Freedman, and S.M. Gapstur Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: cohort Consortium vitamin D Pooling Project of rarer cancers American Journal of Epidemiology 172 1 2010 Jul 1 58 69
4. M.Y. Wei, and E.L. Giovannucci Vitamin D and multiple health outcomes in the Harvard cohorts Molecular Nutrition & Food Research 54 8 2010 Aug 1114 1126
5. K.K. Deeb, D.L. Trump, and C.S. Johnson Vitamin D signalling pathways in cancer: potential for anticancer therapeutics Nature Reviews Cancer 7 9 2007 Sep 684 700 (Pubitemid 47327412)
6. A.J. Brown, A. Dusso, and E. Slatopolsky Vitamin D American Journal of Physiology 277 2 Pt 2 1999 Aug F157 F175
7. J. Ahn, U. Peters, and D. Albanes Serum vitamin D concentration and prostate cancer risk: a nested case-control study Journal of the National Cancer Institute 100 11 2008 Jun 4 796 804 (Pubitemid 351809669)
8. W. Banach-Petrosky, X. Ouyang, and H. Gao Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice Clinical Cancer Research 12 19 2006 Oct 1 5895 5901 (Pubitemid 44629623)
9. I. Chung, G. Han, and M. Seshadri Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo Cancer Research 69 3 2009 Feb 1 967 975
10. K.W. Colston, S.Y. James, and E.A. Ofori-Kuragu Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro British Journal of Cancer 76 8 1997 1017 1020 (Pubitemid 27434657)
11. R.H. Getzenberg, B.W. Light, and P.E. Lapco Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system Urology 50 6 1997 Dec 999 1006 (Pubitemid 28021128)
12. F. Jiang, J. Bao, and P. Li Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase The Journal of Biological Chemistry 279 51 2004 Dec 17 53213 53221 (Pubitemid 40051824)
13. A.V. Krishnan, D.M. Peehl, and D. Feldman Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression Journal of Cellular Biochemistry 88 2 2003 Feb 1 363 371 (Pubitemid 36119910)
14. Y. Ma, W.D. Yu, D.L. Trump, and C.S. Johnson 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models Cancer 116 13 2010 Jul 1 3294 3303
15. K. Nakagawa, A. Kawaura, and S. Kato 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer Carcinogenesis 26 2 2005 Feb 429 440 (Pubitemid 40246565)
16. H.G. Palmer, M. Sanchez-Carbayo, and P. Ordonez-Moran Genetic signatures of differentiation induced by 1alpha, 25-dihydroxyvitamin D3 in human colon cancer cells Cancer Research 63 22 2003 Nov 15 7799 7806 (Pubitemid 37466712)
17. X. Zhang, F. Jiang, and P. Li Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089 Clinical Cancer Research 11 1 2005 Jan 1 323 328 (Pubitemid 40075811)
18. M.F. Holick Vitamin D: a D-Lightful Solution for health Journal of Investigative Medicine 2011 Mar 16
19. M.F. Holick Vitamin D deficiency in 2010: health benefits of vitamin D and sunlight: a D-bate Nature Reviews Endocrinology 7 2 2011 Feb 73 75
20. M.F. Holick Vitamin D: evolutionary, physiological and health perspectives Current Drug Targets 12 1 2011 Jan 4 18
21. Dietary reference intakes for calcium and vitamin D November 2010 [Institute of Medicine consensus report]
22. A.C. Ross The 2011 report on dietary reference intakes for calcium and vitamin D Public Health Nutrition 14 5 2011 May 938 939
23. A.C. Ross, J.E. Manson, and S.A. Abrams The 2011 dietary reference intakes for calcium and vitamin d: what dietetics practitioners need to know Journal of the American Dietetic Association 111 4 2011 Apr 524 527
24. A.C. Ross, J.E. Manson, and S.A. Abrams The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know The Journal of Clinical Endocrinology & Metabolism 96 1 2011 Jan 53 58
25. R.P. Heaney, and M.F. Holick Why the IOM recommendations for vitamin D are deficient Journal of Bone and Mineral Research 2011 Jan 4
26. A. Arabi, R. El Rassi, and G. El-Hajj Fuleihan Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes Nature Reviews Endocrinology 6 10 2010 Oct 550 561
27. C.F. Garland, and F.C. Garland Do sunlight and vitamin D reduce the likelihood of colon cancer? International Journal of Epidemiology 9 3 1980 Sep 227 231 (Pubitemid 11238851)
28. M.H. Ahonen, L. Tenkanen, and L. Teppo Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) Cancer Causes and Control 11 9 2000 Oct 847 852
29. E.R. Bertone-Johnson, W.Y. Chen, and M.F. Holick Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer Cancer Epidemiology, Biomarkers & Prevention 14 8 2005 Aug 1991 1997 (Pubitemid 41161213)
30. Y. Cui, and T.E. Rohan Vitamin D, calcium, and breast cancer risk: a review Cancer Epidemiology, Biomarkers & Prevention 15 8 2006 Aug 1427 1437 (Pubitemid 44299311)
31. C.F. Garland, G.W. Comstock, and F.C. Garland Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study Lancet 2 8673 1989 Nov 18 1176 1178 (Pubitemid 19275448)
32. E. Giovannucci, Y. Liu, and E.B. Rimm Prospective study of predictors of vitamin D status and cancer incidence and mortality in men Journal of the National Cancer Institute 98 7 2006 Apr 5 451 459
33. M.L. McCullough, S.J. Weinstein, and D.M. Freedman Correlates of circulating 25-hydroxyvitamin D: cohort Consortium vitamin D Pooling Project of rarer cancers American Journal of Epidemiology 172 1 2010 Jul 1 21 35
34. A. Zeleniuch-Jacquotte, L. Gallicchio, and V. Hartmuller Circulating 25-hydroxyvitamin D and risk of endometrial cancer: cohort Consortium vitamin D Pooling Project of rarer cancers American Journal of Epidemiology 172 1 2010 Jul 1 36 46
35. L. Gallicchio, K.J. Helzlsouer, and W.H. Chow Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the cohort Consortium vitamin D Pooling Project of rarer cancers American Journal of Epidemiology 172 1 2010 Jul 1 10 20
36. L. Gallicchio, L.E. Moore, and V.L. Stevens Circulating 25-hydroxyvitamin D and risk of kidney cancer: cohort consortium vitamin D Pooling Project of rarer cancers American Journal of Epidemiology 172 1 2010 Jul 1 47 57
37. W. Zheng, K.N. Danforth, and S.S. Tworoger Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: cohort consortium vitamin D pooling project of rarer cancers American Journal of Epidemiology 172 1 2010 Jul 1 70 80
38. R.Z. Stolzenberg-Solomon, E.J. Jacobs, and A.A. Arslan Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers American Journal of Epidemiology 172 1 2010 Jul 1 81 93
39. A.M. Mondul, S.J. Weinstein, and S. Mannisto Serum vitamin D and risk of bladder cancer Cancer Research 70 22 2010 Nov 15 9218 9223
40. B.R. Konety, J.P. Lavelle, and G. Pirtskalaishvili Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo Journal of Urology 165 1 2001 Jan 253 258
41. T. Higashi, S. Homma, and H. Iwata Characterization of urinary metabolites of vitamin D(3) in man under physiological conditions using liquid chromatography-tandem mass spectrometry Journal of Pharmaceutical and Biomedical Analysis 29 5 2002 Jul 31 947 955 (Pubitemid 34692596)
42. M. Thierry-Palmer, V.M. Henderson, and R.E. Hammali Black and white female adolescents lose vitamin D metabolites into urine The American Journal of the Medical Sciences 335 4 2008 Apr 278 283 (Pubitemid 351548646)
43. H. Tanaka, E. Abe, and C. Miyaura 1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60) Biochemical Journal 204 3 1982 Jun 15 713 719
44. C. Miyaura, E. Abe, and T. Kuribayashi 1 alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells Biochemical and Biophysical Research Communications 102 3 1981 Oct 15 937 943 (Pubitemid 12213816)
45. E. Abe, C. Miyaura, and H. Sakagami Differentiation of mouse myeloid leukemia cells induced by 1 alpha, 25-dihydroxyvitamin D3 Proceedings of the National Academy of Sciences 78 8 1981 Aug 4990 4994 (Pubitemid 12225607)
46. A.V. Krishnan, D.L. Trump, and C.S. Johnson The role of vitamin D in cancer prevention and treatment Endocrinology Metabolism Clinics of North America 39 2 2010 Jun 401 418 [table of contents]
47. D.L. Trump, K.K. Deeb, and C.S. Johnson Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy The Cancer Journal 16 1 2010 Jan-Feb 1 9
48. T.M. Beer, D. Lemmon, and B.A. Lowe High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma Cancer 97 5 2003 Mar 1 1217 1224 (Pubitemid 36237307)
49. C. Gross, T. Stamey, and S. Hancock Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) Journal of Urology 159 6 1998 Jun 2035 2039 discussion 9-40
50. D.L. Trump, D.M. Potter, and J. Muindi Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer Cancer 106 10 2006 May 15 2136 2142 (Pubitemid 43673234)
51. T.M. Beer, and A. Myrthue Calcitriol in cancer treatment: from the lab to the clinic Molecular Cancer Therapeutics 3 3 2004 Mar 373 381 (Pubitemid 39193713)
52. T.M. Beer, M.M. Javle, and C.W. Ryan Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer Cancer Chemotherapy and Pharmacology 59 5 2007 Apr 581 587 (Pubitemid 46295122)
53. M.K. Chadha, L. Tian, and T. Mashtare Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer Cancer 116 9 2010 May 1 2132 2139
54. M.G. Fakih, D.L. Trump, and J.R. Muindi A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors Clinical Cancer Research 13 4 2007 Feb 15 1216 1223 (Pubitemid 46424063)
55. J.R. Muindi, C.S. Johnson, and D.L. Trump A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology 65 1 2009 Dec 33 40
56. J.R. Muindi, Y. Peng, and D.M. Potter Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel Clinical Pharmacology & Therapeutics 72 6 2002 Dec 648 659 (Pubitemid 36021004)
57. J.L. Osborn, G.G. Schwartz, and D.C. Smith Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer Urologic Oncology 1 5 1995 Sep-Oct 195 198
58. G. Wilding, P. Soulie, and D. Trump Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer Cancer 106 9 2006 May 1 1917 1924 (Pubitemid 43673206)
59. T.M. Beer, C.W. Ryan, and P.M. Venner Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators Journal of Clinical Oncology 25 6 2007 Feb 20 669 674 (Pubitemid 350002922)
60. H.I. Scher, X. Jia, and K. Chi Randomized, Open-Label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer Journal of Clinical Oncology 2011 Apr 11
61. J.R. Muindi, D.M. Potter, and Y. Peng Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation Cancer Chemotherapy and Pharmacology 56 5 2005 Nov 492 496 (Pubitemid 41549151)
62. T.M. Beer, M. Munar, and W.D. Henner A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation Cancer 91 12 2001 Jun 15 2431 2439 (Pubitemid 32552832)
63. E. Hellstrom, K.H. Robert, and J. Samuelsson Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG) European Journal of Haematology 45 5 1990 Nov 255 261
64. M. Petrini, F. Caracciolo, and M. Corini Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia: pilot study Haematologica 76 3 1991 May-Jun 200 203
65. D. Ferrero, B. Bruno, and P. Pregno Combined differentiating therapy for myelodysplastic syndromes: a phase II study Leukemia Research 20 10 1996 Oct 867 876 (Pubitemid 26400757)
66. C.A. Slapak, J.F. Desforges, and T. Fogaren Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol American Journal of Hematology 41 3 1992 Nov 178 183
67. S. Masuda, and G. Jones Vitamin D analogs-drug design based on proteins involved in vitamin D signal transduction Current Drug Targets - Immune, Endocrine & Metabolic Disorders 3 1 2003 Mar 43 66
68. C.M. Hansen, K.J. Hamberg, and E. Binderup Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation Current Pharmaceutical Design 6 7 2000 May 803 828 (Pubitemid 30396417)
69. P. Bareis, G. Bises, and M.G. Bischof 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression Biochemical and Biophysical Research Communications 285 4 2001 Jul 27 1012 1017 (Pubitemid 32918038)
70. T.C. Chen, L. Wang, and L.W. Whitlatch Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer Journal of Cellular Biochemistry 88 2 2003 Feb 1 315 322 (Pubitemid 36119904)
71. A.M. Nomura, G.N. Stemmermann, and J. Lee Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States) Cancer Causes and Control 9 4 1998 Aug 425 432 (Pubitemid 28466695)
72. U. Segersten, P. Correa, and M. Hewison 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands The Journal of Clinical Endocrinology & Metabolism 87 6 2002 Jun 2967 2972 (Pubitemid 34655371)
73. E.L. Ding, S. Mehta, and W.W. Fawzi Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial International Journal of Cancer 122 8 2008 Apr 15 1690 1694 (Pubitemid 351413414)
74. T.C. Woo, R. Choo, and M. Jamieson Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy Nutrition and Cancer 51 1 2005 32 36 (Pubitemid 40365979)
75. E. Amir, C.E. Simmons, and O.C. Freedman A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases Cancer 116 2 2010 Jan 15 284 291
76. D.C. Smith, C.S. Johnson, and C.C. Freeman A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy Clinical Cancer Research 5 6 1999 Jun 1339 1345 (Pubitemid 29282937)
77. T.M. Beer Development of weekly high-dose calcitriol based therapy for prostate cancer Urologic Oncology 21 5 2003 Sep-Oct 399 405 (Pubitemid 38534184)
78. T.M. Beer, M. Javle, and G.N. Lam Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer Clinical Cancer Research 11 21 2005 Nov 1 7794 7799 (Pubitemid 41611623)
79. K.M. Rassnick, J.R. Muindi, and C.S. Johnson In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors Cancer Chemotherapy and Pharmacology 62 5 2008 Oct 881 891
80. J. Abe-Hashimoto, T. Kikuchi, and T. Matsumoto Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen Cancer Research 53 11 1993 Jun 1 2534 2537 (Pubitemid 23168018)
81. C.N. Sternberg, S.M. Donat, and J. Bellmunt Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer Urology 69 1 2007 Jan 62 79 (Pubitemid 46186484)
82. S.F. Rashid, J.S. Moore, and E. Walker Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A Oncogene 20 15 2001 Apr 5 1860 1872 (Pubitemid 32458696)
83. S. Swami, A.V. Krishnan, and D.M. Peehl Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity Molecular and Cellular Endocrinology 241 1-2 2005 Sep 28 49 61 (Pubitemid 41262171)
84. T.W. Flaig, A. Barqawi, and G. Miller A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer Cancer 107 2 2006 Jul 15 266 274 (Pubitemid 44036555)
85. T.M. Beer, K.M. Eilers, and M. Garzotto Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer Journal of Clinical Oncology 21 1 2003 Jan 1 123 128
86. T.M. Beer, K.M. Hough, and M. Garzotto Weekly high-dose calcitriol and docetaxel in advanced prostate cancer Seminars in Oncology 28 4 Suppl. 15 2001 Aug 49 55 (Pubitemid 32947552)
87. B.W. Light, W.D. Yu, and M.C. McElwain Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system Cancer Research 57 17 1997 Sep 1 3759 3764 (Pubitemid 27381220)
88. P.A. Hershberger, W.D. Yu, and R.A. Modzelewski Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis Clinical Cancer Research 7 4 2001 Apr 1043 1051 (Pubitemid 32708744)
89. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer The New England Journal of Medicine 351 15 2004 Oct 7 1502 1512 (Pubitemid 39315317)
90. T. Gulliford, J. English, and K.W. Colston A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer British Journal of Cancer 78 1 1998 Jul 6 13 (Pubitemid 28276762)
91. T.R. Evans, K.W. Colston, and F.J. Lofts A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer British Journal of Cancer 86 5 2002 Mar 4 680 685 (Pubitemid 34250805)
92. K. Dalhoff, J. Dancey, and L. Astrup A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma British Journal of Cancer 89 2 2003 Jul 21 252 257 (Pubitemid 36976311)
93. G.G. Schwartz, D. Eads, and C. Naczki 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo Cancer Biology and Therapy 7 3 2008 Mar 430 436 (Pubitemid 351847063)
94. G.G. Schwartz, M.C. Hall, and D. Stindt Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer Clinical Cancer Research 11 24 Pt 1 2005 Dec 15 8680 8685 (Pubitemid 43005917)